Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals’ Q1 2026 earnings miss shows a deep revenue gap and a red‑inked business model, urging investors to question its CNS drug pipeline and profitability strategy.

Tonix Pharmaceuticals launches TONMYATM, a sublingual cyclobenzaprine for fibromyalgia muscle spasms, boosting its CNS therapy pipeline and stock confidence.

Tonix’s new sublingual TONMYA® shows superior PK and FDA approval, targeting fibromyalgia sleep‑related symptoms and positioning the company as a CNS innovation leader.

Tonix Pharmaceuticals: pioneering CNS disorder therapies for fibromyalgia and PTSD, growing R&D pipeline and investor resilience despite market volatility.

Tonix Pharmaceuticals faces stock volatility while pushing breakthrough CNS therapies for fibromyalgia and PTSD, balancing bold innovation against financial uncertainty.

Tonix Pharmaceuticals reports a loss but beats revenue expectations, highlighting promising FM and PTSD drug progress and potential upside for investors.

Tonix Pharmaceuticals (TNXP) explores CNS drug breakthroughs for fibromyalgia & PTSD amid volatile biotech markets—learn its pipeline, financial outlook, and investor updates.

Tonix Pharmaceuticals focuses on CNS disorders, with Phase 3 data on TONMYA™ for fibromyalgia and PTSD, while its stock reflects the volatile biotech market and investor hopes for breakthrough therapies.

Tonix Pharmaceuticals faces investor doubt as its stock plummets, lack of new milestones, and negative earnings raise concerns about future pain‑management prospects.

Tonix Pharmaceuticals (TNXP) gains 5% pre‑market as investors eye its CNS‑focused pipeline for fibromyalgia and PTSD, amid rising demand for precision therapies.